Joseph A Berquist bought $50k of KWR
CEO and President at QUAKER CHEMICAL CORP. 482 shares at an average of $103.62, traded May 9, 2025, filed May 13, 2025.
Score components
- +25RoleCEO
- +7Trade size$50k at market
- 0Relative to holdingsHoldings up 4.1%
- +18Price context7% above the 52-week low; 42% below the 52-week high
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000081362-25-000065, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 9, 2025 | POpen-market purchase Common Stock | +482 | $103.62 | $50k | 12,243 | May 13, 2025 |
Related signals
Other insiders at QUAKER CHEMICAL CORP and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 31Weak | KWRsell QUAKER CHEMICAL CORP | Jeffrey Kutz VP, Chief Accounting Officer | $35k 251 shares | -40% | |
| 23Weak | QUAKER CHEMICAL CORP | Jeewat Bijlani EVP, Chief Strategy Officer | $107k 645 shares | -12% | |
| 47Moderate | QUAKER CHEMICAL CORP | David Slinkman SVP - Chief Technology Officer | $285k 1,700 shares | -38% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.